LEQEMBI IQLIK® SELF-INJECTIONS NOW FDA APPROVED

for early Alzheimer’s disease from
the start of treatment. Learn more

Your LEQEMBI IQLIK dose requires 2 injections. At least your first 2 doses are given under the guidance of a healthcare provider.

Leqembi IQLIK
Leqembi IQLIK

Your LEQEMBI IQLIK dose requires 2 injections.
At least your first 2 doses are given under
the guidance of a healthcare provider.

leh kem' bee LEQEMBI speaker speaker speaker active
leh kan' uh mab lecanemab speaker speaker active
LEQEMBI i-click LEQEMBI IQLIK speaker speaker speaker active
Medication Guide

  • For US residents only

Find a
specialist

LEQEMBI is the #1* prescribed anti-amyloid treatment proven to significantly slow the progression† of early Alzheimer’s disease

It’s the only anti-amyloid treatment that:

Works 2 ways

to fight early Alzheimer’s disease

Offers treatment options

with self-injections or IV infusions

Has maintenance dosing

to continue slowing progression after 18 months

*Purple Lab prescription data from 7/24 to 3/26.

†Based on an 18-month study; compared with people not taking LEQEMBI. LEQEMBI does not cure Alzheimer’s disease or stop its progression.

Treatment options
to fit your life

Together, you and your
healthcare provider can decide
how to get started on LEQEMBI.

Self-injections with
LEQEMBI IQLIK

The power to slow
progression in the palm of
your
hand. LEQEMBI IQLIK ) is an
autoinjector that you or a care partner uses to inject under the skin (subcutaneous injection).

Learn about self-injections

IV infusions with LEQEMBI

LEQEMBI is also available as an
intravenous (IV) infusion. This means a
needle is placed in a vein in your arm to
give you the medicine.

Learn about IV infusions

Maintenance dosing

LEQEMBI lets you keep slowing progression after 18 months
with self-injections or
infusions. Both LEQEMBI IQLIK self-injections and LEQEMBI IV infusions have
maintenance dosing options. If you and your healthcare provider decide maintenance treatment is right for you, continuing on LEQEMBI may help you keep seeing the benefits
of slowing progression.

See how LEQEMBI works
in 2 ways

Learn more
Quotation mark icon

We have a busy schedule, so we
wanted a treatment that fit
into our life.

LEONARD

LEQEMBI IQLIK PATIENT

People shown were compensated for their time, and information is accurate as of February 2026. Quotes reflect personal experiences, which may vary.

IMPORTANT SAFETY INFORMATION

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

WHAT IS LEQEMBI?

LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

IMPORTANT SAFETY
INFORMATION

What is the most important information I should know about LEQEMBI?

LEQEMBI can cause serious side effects, including: ARIA (Amyloid-Related Imaging Abnormalities). ARIA is a side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.

  • ARIA commonly shows up as temporary swelling in areas of the brain that usually goes away over time

  • Small spots of bleeding in or on the surface of the brain can occur

  • Less often, larger areas of bleeding in the brain can occur

  • Most people with ARIA don’t have any symptoms. However, some people may notice:

    – headache

    – confusion

    – dizziness

    – vision changes

    – nausea

    – difficulty walking

    – seizures

    – difficulty speaking

    – muscle weakness

  • Some people have a gene called ApoE4 that may increase the risk of ARIA. Talk to your healthcare provider about testing to see if you have
    this gene

  • You may be at a higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving LEQEMBI. Talk to your healthcare provider to see if any of the medicines you’re taking increase this risk

  • Your healthcare provider will check for ARIA with MRI (magnetic resonance imaging) scans before you start LEQEMBI and
    during treatment

  • You should carry information that says you are receiving LEQEMBI, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms

Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.

Serious allergic reactions:

Do not receive LEQEMBI if you have serious allergic reactions to LEQEMBI, LEQEMBI IQLIK, or any of the ingredients.

  • Tell your healthcare provider and get medical help right away if you notice any symptoms during or after treatment with LEQEMBI, including:

    – swelling of the face, lips, mouth, or tongue

    – itchy bumps on the skin, also known as hives

    – difficulty breathing

Infusion-related reactions:

  • Infusion-related reactions are a common side effect that can occur during or after completion with LEQEMBI injection into a vein (intravenously), which can be serious. Tell your healthcare provider right away if you notice any of these symptoms:

    – fever

    – flu-like symptoms (chills, body aches, feeling shaky, joint pain)

    – nausea and/or vomiting

    – dizziness or lightheadedness

    – fast or slow heart rate, or feeling like your chest is pounding

    – difficulty breathing or shortness of breath

    – changes in blood pressure

  • If you have an infusion-related reaction, your healthcare provider may give you medicines before your next infusion to lower the chance of having a reaction

Injection-related reactions:

  • Injection-related reactions may occur with LEQEMBI injection under the skin (subcutaneous injection with LEQEMBI IQLIK). Tell your healthcare provider if you notice any of these symptoms during or after an injection:

    – redness, swelling, heat, pain, itching, rash, bump, bruising, and blood collection under the skin at the injection site

    – headache, chills, fatigue, or fever may also be observed after an injection

The most common side effects of LEQEMBI include infusion-related reactions with LEQEMBI injected into a vein, ARIA, and headache.

These are not all the possible side effects of LEQEMBI. Call your doctor for more information and medical advice about side effects. You may report side effects to the FDA at or call 1-800-FDA-1088.

Before receiving LEQEMBI, tell your healthcare provider about:

  • All your medical conditions, including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if LEQEMBI could harm your unborn or breastfeeding baby

  • All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin)

LEQEMBI (lecanemab-irmb) is available as:

  • Intravenous infusion: 100 mg/mL

  • Subcutaneous injection: 200 mg/mL

Please see Medication Guide with Instructions for Use and full Prescribing Information, including Boxed WARNING, for LEQEMBI.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries. This Website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved ones’, personal medical needs. Individual responses to treatment may vary.

Eisai logo
Biogen logo

© 2026 Eisai Inc. and Biogen.
LEQE-US5519 August 2026
All trademarks are the property of their respective owners.
LEQEMBI®, LEQEMBI IQLIK®, and LEQEMBI Companion® are registered trademarks of Eisai R&D Management Co., Ltd.